Suchergebnisse - "Asselah, Tarik"

PubPharm (51)

1

Phase 3, Multicenter Open-Label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosis

enthalten in: Liver international : official journal of the International Association for the Study of the Liver | 2020

von Abergel, A. | Asselah, T. | Mallat, A. | +19

2

Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use : An integrated analysis of 7 phase III studies

enthalten in: Drug and alcohol dependence | 2019

von Foster, G. | Dore, G. | Wang, S. | +12

3

Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection : A pooled analysis

enthalten in: Liver international : official journal of the International Association for the Study of the Liver | 2018

von Asselah, T. | Reesink, H. | Gerstoft, J. | +10

4

Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4 : the ANRS HC32 QUATTRO study

enthalten in: European journal of gastroenterology & hepatology | 2018

von Roulot, D. | Thibault, V. | Laforest, C. | +17

CommentIn: Eur J Gastroenterol Hepatol. 2018 Jul;30(7):807-808. - PMID 29847527

5

Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response

enthalten in: PloS one | 2017

von Asselah, T. | Moreno, C. | Sarrazin, C. | +12

6

Simple Predictive Model for Identifying Patients with Chronic Hepatitis C and Hepatitis C Virus Genotype 4 Infection with a High Probability of Sustained Virologic Response with Peginterferon Alfa-2a/Ribavirin : Pooled Analysis of Data from Two Large, International Cohort Studies

enthalten in: Advances in therapy | 2016

von Asselah, T. | Esmat, G. | Sanai, F. | +4

7

Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I) : a multicentre, phase 3, randomised open-label trial

enthalten in: The lancet. Gastroenterology & hepatology | 2016

von Asselah, T. | Hézode, C. | Qaqish, R. | +11

CommentIn: Lancet Gastroenterol Hepatol. 2016 Sep;1(1):3-4. - PMID 28404109

8

Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II) : a multicentre, phase 3, partly randomised open-label trial

enthalten in: The lancet. Gastroenterology & hepatology | 2016

von Waked, I. | Shiha, G. | Qaqish, R. | +12

CommentIn: Lancet Gastroenterol Hepatol. 2016 Sep;1(1):3-4. - PMID 28404109

9

Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents

enthalten in: The American journal of gastroenterology | 2016

von Shiffman, M. | Rustgi, V. | Bennett, M. | +7

ErratumIn: Am J Gastroenterol. 2016 Jul;111(7):1077. - PMID 27356843

10

Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1 : pooled analysis of two phase 3 trials

enthalten in: Annals of hepatology | 2016

von Jensen, D. | Asselah, T. | Dieterich, D. | +27

1
2
3
4
5
6
Nächster »
[6]